Denali Therapeutics (DNLI – Research Report) received a Buy rating and a $50.00 price target from SVB Securities analyst Marc Goodman today. The company’s shares closed last Friday at $31.47.
According to TipRanks, Goodman is a 4-star analyst with an average return of 2.9% and a 48.08% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Marinus, and Biogen.
Denali Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $58.40, an 85.57% upside from current levels. In a report released on January 25, Morgan Stanley also maintained a Buy rating on the stock with a $65.00 price target.
See the top stocks recommended by analysts >>
Based on Denali Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $3.56 million and a GAAP net loss of $103.3 million. In comparison, last year the company earned a revenue of $5.29 million and had a GAAP net loss of $84.59 million
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DNLI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Read More on DNLI:
- Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial
- Centogene, Denali extend observational study on Parkinson’s disease genetics
- Denali Therapeutics announces 2023 milestones
- Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
- Denali interim P1b study results in ALS ‘positive,’ says Cantor Fitzgerald